M+PAC

Indications

• Community-acquired pneumonia
• Hospital-acquired pneumonia
• Ventilator-associated pneumonia

Dosage

Children: Refer to the BNF for Children for specific pediatric dosing instructions, as the recommended dose may vary depending on the age and weight of the child.

Adults: The recommended adult dose of hyoscyamine is typically 0.125-0.25 mg orally, 3-4 times a day. However, this dose may vary depending on the specific indication and patient response.

Mechanism of action

Hydrophneumonia acts as a broad-spectrum antibiotic, inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall. This leads to the disruption of the bacterial cell wall and ultimately, cell death.

Pharmacodynamics

Hyoscyamine's anticholinergic effects include reduced salivation, bronchial secretions, and gastrointestinal motility. It also causes dilation of pupils, increased heart rate, and decreased sweating.

Pharmacokinetics

Hyoscyamine is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1-2 hours. It is extensively metabolized by the liver, primarily through the cytochrome P450 system, and has a half-life of approximately 3-4 hours.

Contra-indications

• Hypersensitivity to the active substance or any of the excipients
• Severe renal impairment

Adverse effects

• Headache
• Nausea
• Diarrhoea
• Vomiting
• Rash
• Hypersensitivity reactions

Interactions

• May increase the risk of bleeding when co-administered with warfarin or other anticoagulants
• May increase the risk of nephrotoxicity when co-administered with other nephrotoxic agents

Precautions

• Monitor liver function tests
• Monitor renal function tests
• Monitor for signs of hypersensitivity reactions

Pregnancy

Use only if the potential benefits outweigh the risks.

Breast-feeding

Unknown

Storage

Store in a cool, dry place. Protect from light.

Formulations

• Tablets
• Injectable solution
• Powder for reconstitution

Indications

• Mycoplasma pneumonia
• Atypical pneumonia
• Respiratory tract infections
• Sinusitis
• Bronchitis
• Chronic cough

Dosage

Children: Refer to specific antibiotic guidelines as the dosage depends on the antibiotic chosen for treatment

Adults: Refer to specific antibiotic guidelines as the dosage depends on the antibiotic chosen for treatment.

Mechanism of action

Mycoplasma species, particularly Mycoplasma pneumoniae, adhere to the respiratory epithelial cells and disrupt normal cellular processes. They utilize surface proteins and lipids to anchor themselves to host cells, leading to cell damage through inflammatory responses. They do not produce toxins but can induce host immune responses that contribute to the pathogenicity of the infection.

Pharmacodynamics

Mycoplasma are unique bacteria that lack a cell wall, which makes them resistant to many common antibiotics, such as penicillins and cephalosporins. The treatment of infections caused by Mycoplasma typically involves the use of antibiotics that target protein synthesis, such as macrolides (e.g., azithromycin) or tetracyclines (e.g., doxycycline). These antibiotics inhibit bacterial growth by disrupting essential processes within the bacteria, leading to cell death or stasis.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat Mycoplasma infections can vary. For example, macrolides are well-absorbed orally and have good tissue penetration, allowing them to reach the site of infection effectively. They are metabolized in the liver and excreted primarily through bile. Tetracyclines also have good oral bioavailability and are distributed widely in body tissues, but should be avoided in children under 8 years due to potential effects on bone and tooth development. The half-lives of these antibiotics can range from several hours to a day, depending on the specific drug and patient factors.

Pregnancy

Mycoplasma infections should be treated with caution during pregnancy. The use of antibiotics may be necessary, but the choice of medication should consider safety profiles and potential risks to the fetus.

Breast-feeding

Caution is advised when treating Mycoplasma infections in breastfeeding individuals. Certain antibiotics may be excreted in breast milk, so a risk-benefit assessment is essential.

Storage

Store in a cool, dry place away from direct sunlight. Specific conditions may vary depending on the antibiotic used for treatment.